Market revenue in 2023 | USD 796.1 million |
Market revenue in 2030 | USD 1,145.9 million |
Growth rate | 5.3% (CAGR from 2023 to 2030) |
Largest segment | Inactivated (killed) |
Fastest growing segment | Other Vaccines (e.g. Recombinant, DNA, subunit, or toxoids) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Modified/ Attenuated Live, Inactivated (Killed), Other Vaccines (e.g. Recombinant, DNA, subunit, or toxoids) |
Key market players worldwide | Merck & Co Inc, CEVA Inc, Zoetis, Boehringer Ingelheim, Elanco Animal Health Inc, Indian Immunologicals, Biogenesis Bago, Phibro Animal Health Corp Class A, Virbac SA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to swine vaccines market will help companies and investors design strategic landscapes.
Inactivated (killed) was the largest segment with a revenue share of 39.1% in 2023. Horizon Databook has segmented the Asia Pacific swine vaccines market based on modified/ attenuated live, inactivated (killed), other vaccines (e.g. recombinant, dna, subunit, or toxoids) covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is anticipated to grow at the fastest rate during the forecast period. Increased animal population and favorable government initiatives, especially in emerging nations, are expected to propel market growth in the region.
As most Asian nations depend on agricultural output and exports, there is a large supply of livestock animals, resulting in significant growth. Furthermore, rising incidence of infectious diseases in the region, such as Classical Swine Fever (CSF), is driving the product demand.
CSF costs India over INR 400 crores (USD 5.02) every year. As a result, the Indian government is concentrating its efforts on the development of new vaccines. For instance, in February 2020, the ICAR-Indian Veterinary Research Institute launched a novel, locally developed vaccination for CSF management that costs only INR 2 per dosage.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific swine vaccines market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific swine vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account